Verily Powers up Position in Wearables with New FDA Nod
There are new developments surrounding Verily Life Scienceâs prescription-only smartwatch. FDA has granted a new clearance for the South San Francisco-based companyâs Study Watch to measure irregular heartbeats.
The clearance comes one year after Verily received its first 510(k) clearance for ECG for the wrist-worn, sensor-based device. Verily announced in September of 2019 that it collaborated with iRhythm to develop solutions aimed at the Study Watch to improve the screening, diagnosis, and management of patients with atrial fibrillation (AFib).
The collaboration brings together iRhythmâs expertise in artificial intelligence-based arrhythmia diagnosis and Verilyâs advanced health data analytics technologies to address the millions of patients living with undiagnosed AFib.
Terms of the agreement call for iRhythm to make an upfront payment to Verily of $5 million and potential milestone payments of up to $12.75 million upon the achievement of various development and regulatory milestones.
The company said in its parallel to the work with iRhythm, itâs continuing to use the Investigational Study Watch to collect biometric health information, like heart rate and inertial movement, through clinical research programs, including Project Baseline.
Verily, the former life scienceâs division of Google, has been in an interesting place recently. The company has seen some of its ...
Source: MDDI - Category: Medical Devices Authors: Omar Ford Tags: Regulatory and Compliance Digital Health Source Type: news
More News: Arrhythmia | Atrial Fibrillation | Cardiology | Diabetes | Endocrinology | Heart | Heart Transplant | Medical Devices | Mergers and Aquisitions | Partnerships | Science | Study